What is QUICKI?
The Quantitative Insulin Sensitivity Check Index (QUICKI) is a mathematically derived index that estimates insulin sensitivity from fasting insulin and fasting glucose concentrations. It was developed by Katz et al. in 2000 as a simple, practical alternative to the euglycemic hyperinsulinemic clamp, which is the gold standard for measuring insulin sensitivity but is expensive, time-consuming, and impractical for routine clinical use.
QUICKI has been validated against the clamp technique and shows a strong linear correlation (r = 0.78-0.89) across a wide range of insulin sensitivity, from highly sensitive individuals to those with type 2 diabetes. It is particularly useful for epidemiological studies, clinical trials, and screening in primary care settings.
The calculator also computes HOMA-IR (Homeostatic Model Assessment of Insulin Resistance), another widely used surrogate marker. While QUICKI measures insulin sensitivity (higher is better), HOMA-IR measures insulin resistance (lower is better). They are mathematically related and provide complementary information.
QUICKI & HOMA-IR Formulas
QUICKI
Where insulin is in µU/mL and glucose is in mg/dL. The logarithmic transformation normalizes the skewed distribution of fasting insulin values in the population.
HOMA-IR
Where insulin is in µU/mL and glucose is in mg/dL. The constant 405 is a normalization factor (the product of 22.5 × 18, where 22.5 is the normal fasting insulin × glucose product in SI units and 18 converts mmol/L to mg/dL).
Interpreting Results
QUICKI Interpretation
| QUICKI Value | Interpretation | Clinical Significance |
|---|---|---|
| > 0.45 | Normal insulin sensitivity | Healthy metabolic function |
| 0.35 – 0.45 | Moderate sensitivity | Early changes; lifestyle modification recommended |
| 0.30 – 0.35 | Insulin resistant | Significantly impaired; monitor for metabolic syndrome |
| < 0.30 | Severe insulin resistance | High diabetes risk; aggressive intervention needed |
HOMA-IR Interpretation
| HOMA-IR Value | Interpretation |
|---|---|
| < 1.0 | Optimal insulin sensitivity |
| 1.0 – 1.9 | Normal |
| 2.0 – 2.9 | Early insulin resistance |
| ≥ 3.0 | Significant insulin resistance |
Insulin Sensitivity Spectrum
Understanding Insulin Resistance
Insulin resistance is a condition in which cells in the body respond poorly to insulin and cannot efficiently take up glucose from the blood. The pancreas compensates by producing more insulin (hyperinsulinemia) to maintain normal blood glucose levels. Over time, if the pancreatic beta cells cannot keep up with the increased demand, blood glucose levels rise, leading first to prediabetes and eventually to type 2 diabetes.
Insulin resistance is the central pathophysiological feature of metabolic syndrome and type 2 diabetes. It is also associated with:
- Cardiovascular disease: Insulin resistance promotes atherogenesis, dyslipidemia, and hypertension
- Non-alcoholic fatty liver disease (NAFLD): Hepatic insulin resistance drives triglyceride accumulation in the liver
- Polycystic ovary syndrome (PCOS): Insulin resistance and compensatory hyperinsulinemia drive excess androgen production
- Obesity: Both a cause and consequence of insulin resistance, creating a vicious cycle
- Acanthosis nigricans: Darkened skin patches in body folds, a clinical sign of insulin resistance
Metabolic Syndrome
Metabolic syndrome is a cluster of interconnected metabolic abnormalities that substantially increase the risk of cardiovascular disease and type 2 diabetes. Insulin resistance is considered the unifying pathological mechanism.
Diagnosis requires 3 or more of the following criteria (ATP III definition):
| Criterion | Threshold |
|---|---|
| Waist circumference | ≥ 102 cm (men) or ≥ 88 cm (women) |
| Triglycerides | ≥ 150 mg/dL (or on treatment) |
| HDL cholesterol | < 40 mg/dL (men) or < 50 mg/dL (women) |
| Blood pressure | ≥ 130/85 mmHg (or on treatment) |
| Fasting glucose | ≥ 100 mg/dL (or on treatment) |
Metabolic syndrome affects approximately 25-35% of adults in developed countries and its prevalence is increasing globally, driven by rising obesity rates and sedentary lifestyles.
Type 2 Diabetes Prevention
Identifying insulin resistance early through tools like QUICKI allows for timely intervention. The landmark Diabetes Prevention Program (DPP) trial demonstrated that lifestyle modification can reduce the risk of progressing from prediabetes to type 2 diabetes by 58%, which is more effective than metformin (31% reduction).
Evidence-based strategies for preventing type 2 diabetes include:
- Weight loss: Even a modest 5-7% weight loss significantly improves insulin sensitivity. For a 90 kg person, this is just 4.5-6.3 kg.
- Regular exercise: 150 minutes/week of moderate-intensity activity (brisk walking, cycling). Both aerobic and resistance exercise improve insulin sensitivity independently.
- Dietary changes: Emphasize whole grains, vegetables, lean proteins, and healthy fats. Reduce refined carbohydrates and added sugars. The Mediterranean diet has shown particular benefit.
- Sleep optimization: Poor sleep quality and duration (<6 hours or >9 hours) are independently associated with insulin resistance.
- Stress reduction: Chronic stress elevates cortisol, which directly opposes insulin action.
- Metformin: Considered for high-risk individuals (BMI ≥ 35, history of gestational diabetes, or progressive hyperglycemia despite lifestyle changes).
Worked Example
A patient has fasting insulin = 15 µU/mL and fasting glucose = 105 mg/dL.
= 1 / (1.176 + 2.021)
= 1 / 3.197
= 0.313
= 1575 / 405
= 3.89
The QUICKI of 0.313 falls in the insulin resistant range (0.30-0.35), and the HOMA-IR of 3.89 confirms significant insulin resistance (≥ 3.0). This patient is at elevated risk for developing type 2 diabetes and should be counseled on lifestyle modifications including weight loss, exercise, and dietary changes. Consider screening for metabolic syndrome components.
Frequently Asked Questions
Which is better, QUICKI or HOMA-IR?
Both indices have been extensively validated and provide similar clinical information. QUICKI has a slightly better linear correlation with the gold-standard clamp technique, especially in the insulin-resistant range. HOMA-IR is more widely used in clinical practice and research literature. Reporting both provides complementary perspectives — QUICKI measures sensitivity (higher = better) while HOMA-IR measures resistance (lower = better).
Do I need to fast before testing?
Yes. Both QUICKI and HOMA-IR require fasting values (typically 8-12 hours overnight fast). Non-fasting values will produce inaccurate results because postprandial insulin and glucose levels are influenced by meal composition, timing, and individual variation in absorption.
Can QUICKI be used to monitor treatment response?
Yes. QUICKI can track changes in insulin sensitivity over time in response to lifestyle modifications, weight loss, or medications like metformin. Serial measurements every 3-6 months can help assess treatment efficacy. An improving QUICKI (rising toward 0.45) indicates improving insulin sensitivity.
What glucose units does this calculator use?
This calculator uses mg/dL for glucose and µU/mL for insulin. If your lab reports glucose in mmol/L, multiply by 18 to convert to mg/dL. If insulin is reported in pmol/L, divide by 6.945 to convert to µU/mL.
Can QUICKI diagnose diabetes?
No. QUICKI assesses insulin sensitivity but does not diagnose diabetes. Diabetes is diagnosed by specific glucose criteria: fasting glucose ≥ 126 mg/dL, HbA1c ≥ 6.5%, 2-hour post-load glucose ≥ 200 mg/dL on OGTT, or random glucose ≥ 200 mg/dL with symptoms. QUICKI is a screening and monitoring tool, not a diagnostic criterion.